Are you a Veteran of the United States Armed Forces?

Please complete a short survey about prostate cancer care for Veterans to help us learn what's working well and what needs improvement in the care Veterans receive.

Veterans prostate cancer care survey Complete the Survey

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer, has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC platform. This approach is intended to work as an adaptor, connecting the patient’s own immune T-cells with tumor cells.

Read more.


Source: Jose Marques Lopes, PHD - Prostate Cancer News Today

Share